MODERNA INC (MRNA) Stock Price, Forecast & Analysis
NASDAQ:MRNA • US60770K1079
MRNA Key Statistics, Chart & Performance
The current stock price of MRNA is 40.11 USD. In the past month the price decreased by -1.16%. In the past year, price increased by 21.58%.
MRNA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MRNA. When comparing the yearly performance of all stocks, MRNA is one of the better performing stocks in the market, outperforming 91.08% of all stocks.
MRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRNA. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
MRNA Financial Highlights
Over the last trailing twelve months MRNA reported a non-GAAP Earnings per Share(EPS) of -8.07. The EPS decreased by -38.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| Debt/Equity | 0 |
MRNA Forecast & Estimates
30 analysts have analysed MRNA and the average price target is 39.68 USD. This implies a price decrease of -1.06% is expected in the next year compared to the current price of 40.11.
For the next year, analysts expect an EPS growth of 12.27% and a revenue growth -41.3% for MRNA
MRNA Ownership
MRNA Latest News, Press Relases and Analysis
MRNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRNA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Stephane Bancel
Employees: 5800
Phone: 16177146500
MODERNA INC / MRNA FAQ
What does MRNA do?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the current price of MRNA stock?
The current stock price of MRNA is 40.11 USD. The price decreased by -0.99% in the last trading session.
Does MODERNA INC pay dividends?
MRNA does not pay a dividend.
What is the ChartMill rating of MODERNA INC stock?
MRNA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting MRNA stock to perform?
30 analysts have analysed MRNA and the average price target is 39.68 USD. This implies a price decrease of -1.06% is expected in the next year compared to the current price of 40.11.
Can you provide the market cap for MODERNA INC?
MODERNA INC (MRNA) has a market capitalization of 15.67B USD. This makes MRNA a Large Cap stock.
Can you provide the ownership details for MRNA stock?
You can find the ownership structure of MODERNA INC (MRNA) on the Ownership tab.